299. Cystic fibrosis
1,592 clinical trials,   1,539 drugs   (DrugBank: 255 drugs),   81 drug target genes,   162 drug target pathways

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02547116
(ClinicalTrials.gov)
December 20209/9/2015Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic FibrosisEpidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic FibrosisCystic Fibrosis;MRSADrug: RifampinJohns Hopkins UniversityNULLSuspended12 YearsN/AAll16Phase 4United States
2NCT02372383
(ClinicalTrials.gov)
October 201420/6/2014Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic FibrosisPharmacokinetic Evaluation of Nontuberculous Mycobacterial Antibiotics in Cystic Fibrosis Versus ControlsCystic FibrosisDrug: Ethambutol;Drug: Rifampin;Drug: Azithromycin;Drug: PancrelipaseUniversity of Colorado, DenverCystic Fibrosis Foundation Therapeutics;Colorado Clinical & Translational Sciences InstituteCompleted16 Years45 YearsBoth32N/AUnited States
3EUCTR2013-000219-25-IT
(EUCTR)
18/07/201312/04/2018MRSA study.Early eradication of S. Aureus (MRSA) in patients with cystic fibrosis: a randomized multicenter study. Patients affected by cystic fibrosis and who present an initial infection of MRSA.;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]Product Name: Rifampin
INN or Proposed INN: RIFAMPICIN
Product Name: Trimethoprim-sulfamethoxazole
INN or Proposed INN: SULFAMETHOXAZOLE
Other descriptive name: TRIMETHOPRIM
Product Name: minocycline
Other descriptive name: MINOCYCLINE HYDROCHLORIDE
AOU MeyerNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 3Italy
4NCT01768663
(ClinicalTrials.gov)
January 201311/1/2013A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult SubjectsA Phase 1, Open-Label Study to Examine the Effect of Ciprofloxacin, Itraconazole, and Rifampin on the Pharmacokinetics of Lumacaftor in Combination With Ivacaftor in Healthy Adult SubjectsCystic FibrosisDrug: Lumacaftor;Drug: Ivacaftor;Drug: Ciprofloxacin;Drug: Itraconazole;Drug: RifampinVertex Pharmaceuticals IncorporatedNULLCompleted18 Years55 YearsBoth80Phase 1United States
5NCT01594827
(ClinicalTrials.gov)
October 20127/5/2012Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)Persistent MRSA Eradication Protocol (PMEP)Cystic FibrosisDrug: Inhaled Vancomycin;Drug: Placebo (Sterile Water);Drug: Rifampin;Drug: Trimethoprim/Sulfamethoxazole (TMP/SMX);Drug: Doxycycline;Drug: Mupirocin Intranasal Creme;Drug: 4% chlorhexidine gluconate liquid skin cleanserJohns Hopkins UniversityCase Western Reserve University;Cystic Fibrosis FoundationCompleted12 YearsN/AAll29Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01349192
(ClinicalTrials.gov)
April 20114/5/2011Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)Cystic Fibrosis;Methicillin-resistant Staphylococcus AureusDrug: Rifampin;Drug: Trimethoprim/Sulfamethoxazole;Drug: Minocycline;Drug: Mupirocin;Drug: chlorhexidine gluconate oral rinse;Drug: 2% Chlorhexidine solution wipes;Behavioral: Environmental DecontaminationUniversity of North Carolina, Chapel HillCF Therapeutics Development Network Coordinating Center;Seattle Children's Hospital;Washington University School of Medicine;University of Washington;University of Colorado, Denver;Baylor College of Medicine;University of Alabama at Birmingham;Cook Children's Medical Center;University of Michigan;University of Florida;University of Texas Southwestern Medical Center;Children's Hospital Medical Center, Cincinnati;St. Louis Children's HospitalTerminated4 Years45 YearsAll47Phase 2United States
7NCT01018368
(ClinicalTrials.gov)
November 200919/11/2009Study of VX-770 and Rifampin in Healthy Male SubjectsAn Open-Label Phase 1 Study to Examine the Effect of Multiple Doses of Rifampin on the Single-Dose Pharmacokinetics of VX 770 in Healthy SubjectsCystic FibrosisDrug: VX-770;Drug: RifampinVertex Pharmaceuticals IncorporatedNULLCompleted18 Years55 YearsMale24Phase 1United States